tazemetostat
Ipsen Acquires Epizyme, Garners Tazverik, Other Oncology Assets
The transaction, slated to close in Q3, will give Ipsen the EZH2 inhibitor, a SETD2 inhibitor, and other preclinical programs involving epigenetic targets.
Dartmouth Spinoff Episteme Prognostics Aims to Bring Precision Epigenetics to Pancreatic Cancer
Premium
The researchers at the startup have developed a microarray test to predict patients' response to chemotherapy based on chromatin accessibility.